Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (panNETs) treated initially with Octreotide LAR and methods of further treatment after relapse - Real-world data

#3588

Introduction: Evaluation of PFS & OS in patients with sporadic, advanced, unresectable, panNET using first line Octreotide therapy need to be further explored.

Aim(s): PFS & OS in patients with panNET treated initially with Octreotide LAR & assessed further therapy approaches after relapse.

Materials and methods: Retrospective review of 374 patients. Study group 41, responses evaluated in RECIST, clinical, biochemical & AEs assessed after each of 4 w follow-up. PFS & OS, utilized standard Kaplan–Meier estimator, Cox proportional model used to assess differences between some predictor factors.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Bednarczuk T, Osowiecka K, Słoniowska A, Roszkowska K,

Keywords: advance, unresectable pancreatic neuroendocrine tumor, initial octreotide LAR therapy, OS, PFS,